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Cancer therapeutics are primarily thought to work by inducing apoptosis in tumor cells. However, various tumor suppressors 
and oncogenes have been shown to regulate senescence in normal cells, and senescence bypass appears to be an important 
step in the development of cancer. Cellular senescence limits the replicative capacity of cells, thus preventing the proliferation 
of cells that are at different stages of malignancy. A recent body of evidence suggests that induction of senescence can be 
exploited as a basis for cancer therapy. 
Introduction 
In simplistic terms, cancer is a disease of uncontrolled cell prolif­
eration occurring at the wrong place at the wrong time, caused 
by oncogenic signals. To counter abnormal cell proliferation, a 
cell can either enter a quiescence-like growth arrest phase, 
undergo apoptosis, or senesce.These antiproliferative programs 
are induced by various tumor suppressors in response to poten­
tial oncogenic signals. In particular, p53 and pRB tumor suppres­
sors are important mediators of quiescence, apoptosis, and 
senescence. The senescence phenomenon was first described 
by Hayflick and Moorhead in human fibroblasts (Hayflick and 
Moorhead, 1961). Senescent cells in culture are identified by 
large cell size, flat vacuolated morphology, inability to synthesize 
DNA, and the presence of the senescence-associated β-galac­
tosidase (SA-β-gal) marker, which is detected by a colorimetric 
assay using X-gal as a substrate at pH 6.0 (Dimri et al., 1995). 
Using the SA-β-gal marker, and other senescence and aging 
biomarkers, several recent studies have demonstrated a role for 
cellular senescence in aging and cancer (reviewed in Itahana et 
al., 2004; Campisi, 2005; Lombard et al., 2005). While the exact 
role of senescence in aging is debatable, its role as a tumor sup­
pressor mechanism is more widely accepted (reviewed in Smith 
and Pereira-Smith, 1996; Itahana et al., 2004). 
The first indication of senescence being a tumor suppressor 
mechanism was obtained by somatic cell hybridization studies 
(Smith and Pereira-Smith, 1996). It was shown that a hybrid cell 
generated by fusion of a tumor (immortal) and a normal (mortal) 
cell always undergoes senescence in culture. Thus, the senes­
cent phenotype is dominant over immortality, which is a reces­
sive trait. Early studies also identified p53 and pRB as two 
principal regulators of senescence (Shay et al., 1991; reviewed 
in Itahana et al., 2004), further supporting the hypothesis of cel­
lular senescence being a tumor suppressor mechanism (dis­
cussed below in detail). What are the senescence-initiating 
signals, and how are these signals transduced to induce a 
senescent phenotype? As described below, several studies 
implicate telomeric and nontelomeric signals in the induction of 
cellular senescence. 
Senescence-initiating signals:Telomere is only the tip of 
the iceberg 
The tips of a chromosome consist of telomere repeats, which 
are capped by telomere binding proteins (reviewed in 
Smogorzewska and de Lange, 2004). In human cells, progres­
sive telomere shortening appears to be the primary cause of 
cellular senescence (Harley et al., 1990; reviewed in Kim et al., 
2002). In most cases, the enzyme telomerase maintains telom­
ere length.The catalytic subunit of telomerase (TERT), together 
with its RNA component (TERC), builds telomere repeats at the 
chromosome ends, which otherwise, owing to asymmetric DNA 
replication, are progressively lost (reviewed in Smogorzewska 
and de Lange, 2004; Kim et al., 2002). Most human somatic 
cells do not contain sufficient telomerase to maintain telomere 
length (Masutomi et al., 2003), resulting in telomere shortening 
after each round of cell division. Exogenous expression of telo­
merase can either increase or stabilize telomere length in nor­
mal human cells, and in some cases results in cell 
immortalization (Bodnar et al., 1998). 
It is thought that telomere shortening beyond a certain limit 
or uncapping of telomere ends triggers a DNA damage 
response, thereby activating a checkpoint mediated by the p53 
pathway, resulting in proliferation arrest. Signals emitted by the 
telomere dysfunction appear to be similar to double-strand DNA 
break (DSB)-induced signals (d’Adda di Fagagna et al., 2003; 
Takai et al., 2003; Gire et al., 2004). Senescent cells are 
enriched in the nuclear foci of phosphorylated histone H2AX (γ-
H2AX), p53 binding protein 53BP1, NBS1, the phosphoS966 
form of SMC1, and MDC1 (d’Adda di Fagagna et al., 2003). 
Moreover, inactivation of CHK1 and CHK2 checkpoint kinases 
can restore S phase progression in senescent cells (d’Adda di 
Fagagna et al., 2003; Gire et al., 2004). A more recent study 
using single cell parameters also suggested that telomere 
shortening-triggered senescence is a DNA damage response 
mediated by the ATM/ATR-p53-p21 pathway (Herbig et al., 
2004). If cellular senescence induced by telomere dysfunction 
in human cells is a DNA damage response, then the DNA dam­
aging agents and factors that mimic DNA damage should be 
able to induce cellular senescence. Indeed, DNA damaging 
agents and other cellular stresses can trigger a senescence-like 
phenotype (reviewed in Ben-Porath and Weinberg, 2004, 
Itahana et al., 2004), characterized by a large, flat morphology 
and the presence of the SA-β-gal marker (Figure 1). 
Apart from DNA damage, certain undefined stress-causing 
signals also induce senescence. For example, senescence in 
cultured murine cells is thought to be due to stress induced by 
culture conditions (Sherr and De Pinho, 2000), which can be 
abrogated by decreasing oxygen concentration used in cultur­
ing these cells (Parrinello et al., 2003). In addition, oncogenic 
and mitogenic signals, such as activated H-RAS, can also 
induce senescence in primary cells (Figure 1). Thus, senes-
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Figure 1. Presenescent cells undergo senescence in response to telomeric 
and nontelomeric signals 
Telomeric signals such as telomere shortening and uncapping of telomere 
ends, as well as nontelomeric signals such as DNA damaging agents, 
oncogenic/mitogenic signaling, and undefined stress signals, induce 
senescence. Undefined stress signals are signals that come from a variety 
of sources, such as culture media. Senescent cells in culture are often iden-
tified by large, flat cell morphology, and stain positively for SA-β-gal marker. 
cence-inducing signals can be telomeric or nontelomeric 
(Figure 1). Senescence induced by nontelomeric signals is 
termed accelerated senescence, premature senescence, 
stress- or aberrant signaling-induced senescence (STASIS), or 
extrinsic senescence (Itahana et al., 2003, 2004). Senescence 
induced by nontelomeric signals may have evolved to protect 
organisms from acute signals that may cause cancer or other 
diseases resulting from faulty DNA replication. 
Tumor suppressor pathways and senescence: Meant for 
each other 
Regardless of the senescence-initiating signals (telomeric or 
nontelomeric), tumor suppressor pathways are critical for gene­
sis and maintenance of the senescent phenotype in human and 
mouse cells. However, tumor suppressor pathways that pertain 
to senescence differ in human and mouse cells (Figure 2). In 
human cells, telomeric signals principally engage the p53-p21­
pRB pathway (Figure 2A), while nontelomeric signals engage 
both the p53-p21-pRB and p16-pRB pathways (Figure 2A). In 
mouse cells, the ARF-p53-p21-pRB pathway is the dominant 
pathway of senescence (Figure 2B). However, pRB function in 
mouse cells can be substituted by pRB-related proteins p107 
and p130 (reviewed in Itahana et al., 2004). It has also been 
suggested that p21 may not be the sole conduit of p53 during 
senescence induction in mouse cells (Pantoja and Serrano, 
1999). Thus, other p53 targets may also participate in induction 
of senescence in mouse cells (Figure 2B). It is likely that these 
other p53 targets also contribute to senescence in human cells. 
Various other tumor suppressors and oncogenes also impinge 
upon these pathways of senescence and modulate them 
accordingly (Figure 2) (described below). Nonetheless, p53 and 
pRB remain the two main regulators of cellular senescence in 
human and mouse cells. 
p53, the master regulator of senescence 
Depending on the severity of damage to the genome, p53 can 
activate genetic programs that halt cell proliferation transiently 
Figure 2. Telomeric and nontelomeric signals induce senescence via tumor 
suppressor pathways in human and mouse cells 
Induction of p21 and p16 by senescence-inducing signals results in inhibi-
tion of activity of CDK2 and CDK4/6. Downregulation of activity of these 
pRB kinases leads to pRB hypophosphorylation, which results in cell cycle 
arrest during senescence. Regulators of senescence pathways in human 
and mouse cells include PML, MDM2, ID1, Bmi-1, CBX7, and Seladin-1. In 
mouse cells, tumor suppressor ARF is negatively regulated by two potential 
oncogenes, TBX2 and Pokemon, and positively regulated by DMP-1. 
A: In human cells, telomeric and nontelomeric signals induce senescence 
primarily via the p53-p21-pRB pathway. Nontelomeric signals also induce 
the p16-pRB pathway of senescence in human cells. 
B: Mouse cells undergo senescence via the ARF-p53-p21-pRB pathway in 
response to nontelomeric signals. Mouse cells do not senesce by the telom-
eric signal-induced pathway of senescence. 
Solid lines indicate principal pathways of senescence, while dotted lines 
indicate auxiliary pathways that can modulate senescence. The red let-
ters indicate tumor suppressors and growth inhibitors, while the green letters 
indicate oncogenes and growth promoters. 
(G1 and G2 cell cycle arrest) or permanently (senescence), or 
eliminate the cell altogether (apoptosis). Evidence for its role in 
senescence comes from several studies. First, as described 
earlier, it has been clearly shown that telomere shortening or 
dysfunction induces a DNA damage response mediated by p53. 
Second, abrogation of the p53-p21 pathway by various strate­
gies can bypass senescence in human and mouse cells (Shay 
et al., 1991; Brown et al., 1997; Dirac and Bernards, 2003; 
Beausejour et al. 2003). Third, enforced expression of p53 or 
p21 in certain cell types can induce a senescence-like pheno­
type (Itahana et al., 2001). Finally, a variety of stimuli induce 
senescence in a p53/p21-dependent manner (Itahana et al., 
2001, 2004). 
It is interesting to note that studies using DNA tumor viruses 
to inactivate p53 suggested that p53 inactivation only extends 
the replicative life span, and complete abrogation of senes­
cence leading to crisis requires pRB inactivation as well (Shay 
et al., 1991). However, more recent studies using either somatic 
cell knockout or an RNAi (RNA interference) approach suggest 
that p53 and p21 inactivation can lead to complete abrogation 
of senescence and induction of a crisis-like phenotype (Brown 
et al., 1997, Dirac and Bernards, 2003, and our unpublished 
data). How does p53 induction during senescence cause cell 
cycle arrest? Most studies suggest that p21 induction by p53 
inhibits CDK2/Cyclin E activity. Activity of CDK4/Cyclin Ds can 
also be inhibited by p21. Inhibition of activity of CDKs by p21 
results in hypophosphorylation of pRB, which very likely medi-
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ates cell cycle arrest during senescence (Figure 2) (Itahana et 
al., 2004). 
The role of p53 regulators in senescence 
Tumor suppressor p53 is positively or negatively regulated by a 
plethora of factors (Figure 2) (reviewed in Vousden, 2002). The 
E3 ubiquitin ligases MDM2, PIRH2, and COP1 negatively regu­
late p53 by targeting it for proteosome-mediated degradation 
(reviewed in Lu, 2005). On the other hand, p53 is positively reg­
ulated by ARF (p14ARF in human or p19ARF in mouse), PML, 
PTEN, NPM, p33ING1, and other potential tumor suppressors, 
which posttranslationally stabilize p53 (Weber et al., 1999, 
Leung et al., 2002, Freeman et al., 2003, Bernardi et al., 2004, 
Kurki et al., 2004). In principle, these positive and negative reg­
ulators of p53 can also impact cellular senescence (Figure 2). 
Indeed, p33ING1 is known to be overexpressed in senes­
cent cells (Garkavtsev and Riabowol, 1997), and its overexpres­
sion can induce senescence in proliferating cells (Goeman et al., 
2005). Similarly, nucleophosmin (NPM) overexpression was 
shown to induce senescence in a p53-dependent manner 
(Colombo et al., 2002). On the other hand, NPM also interacts 
with ARF tumor suppressor and inhibits its function (reviewed in 
Zhang, 2004). Interestingly, NPM is mutated in a large number of 
cases of acute myelogenous leukemia (AML) in humans (Falini 
et al., 2005). It is tempting to speculate that NPM mutations in 
these cases may be related to its possible role in senescence. 
PML and p53 pathway of senescence 
PML binds MDM2 and sequesters it into the nucleolus (Bernardi 
et al., 2004), thus protecting p53 from proteosome-mediated 
degradation. As a result, overexpression of PML, and accumula­
tion of PML and MDM2 in the nucleolus after DNA damage, 
results in p53 stabilization (Bernardi et al., 2004). PML is upregu­
lated during cellular senescence (Ferbeyre et al., 2000), and 
induces premature senescence in response to oncogenic H-RAS 
by promoting p53 acetylation (Pearson et al., 2000). Moreover, 
human SIR2, which deacetylates p53, inhibits PML- and p53­
induced premature senescence, further confirming the role of 
PML as a senescence-regulatory protein (Langley et al., 2002). 
More detailed studies have recently suggested that PML 
isoform IV, when overexpressed, induces senescence in human 
fibroblasts in a pRB-dependent manner (Mallette et al., 2004; 
Bischof et al., 2005), and that the cytoplasmic isoform of PML 
induces cellular senescence in response to TGF-β (Lin et al., 
2004). Collectively, these studies suggest that the PML tumor 
suppressor contributes to cellular senescence in human and 
mouse cells. 
ARF, an upstream regulator of p53 pathway and 
senescence 
The INK4a/ARF locus encodes p16INK4a and ARF, which regu­
late pRB and p53 pathways of senescence and tumor suppres­
sion, respectively (reviewed in Lowe and Sherr, 2003; 
Sharpless, 2005). As indicated before, the ARF-p53 pathway is 
the major pathway of senescence in mouse cells. ARF is over­
expressed in cultured senescent mouse embryo fibroblasts 
(MEFs) and upregulated during premature senescence induced 
by onocogenic signals such as activated H-RAS (Kamijo et al., 
1999; reviewed in Lowe and Sherr, 2003; Sharpless, 2005) 
(described below in detail). Although ARF overexpression can 
also promote senescence in human cells (Dimri et al., 2000; 
Wei et al., 2001), it may not be a major regulator of senescence 
in human cells (Wei et al., 2001; reviewed in Sharpless, 2005). 
ARF is thought to antagonize MDM2-mediated ubiquitination 
of p53 through translocation of MDM2 to the nucleolus, thereby 
stabilizing p53 (reviewed in Sherr and Weber, 2000). Although it 
can also inhibit cell proliferation by p53-independent pathways 
(reviewed in Cleveland and Sherr, 2004), ARF probably pro­
motes senescence by regulating the p53 pathway (Dimri et al., 
2000; Wei et al., 2001).The specific transcriptional repressors of 
ARF include TBX2, which was identified in a senescence bypass 
screen (Jacobs et al., 2000), and the protooncogene Pokemon, 
which can bind to the ARF promoter and repress its transcription 
(Maeda et al., 2005). MEFs lacking Pokemon (Zbtb7) exhibit 
constitutive upregulation of p19ARF and undergo premature 
senescence (Maeda et al., 2005). Importantly, TBX2 and 
Pokemon are aberrantly overexpressed in a subset of breast 
cancers and lymphomas, respectively (Jacobs et al., 2000; 
Maeda et al., 2005), suggesting a possible role for these ARF 
regulators in senescence in human cells as well. 
pRB, the second regulator of cellular senescence 
In contrast to p53, the role of pRB in cellular senescence is less 
clear (Itahana et al., 2004). Earlier studies using DNA tumor 
viruses that bind and inactivate pRB clearly indicate that pRB 
cooperates with p53 during cellular senescence (Shay et al., 
1991). More recent studies suggest that perhaps pRB is, in 
some instances, as important as p53 in inducing cellular senes­
cence. Using the Cre-Lox system to delete pRB in senescent 
MEFs, Sage et al. showed that the loss of pRB is sufficient for 
cell cycle entry and the reversal of cellular senescence (Sage et 
al., 2003). In human fibroblasts, loss of pRB by targeted disrup­
tion of one copy followed by the spontaneous loss of its other 
allele results in bypass of replicative senescence and a crisis­
like phenotype similar to that induced by the abrogation of the 
p53-p21 pathway (Wei et al., 2003). Inactivation of an exoge­
nously introduced temperature-sensitive pRB in senescent 
SAOS-2 cells also results in S phase reentry (Alexander et al., 
2003). Collectively, these data suggest that pRB maintains cell 
cycle arrest during senescence in human and mouse cells. 
It is very well established that pRB remains constitutively 
hypophosphorylated in senescent cells (Stein et al., 1999), sug­
gesting downregulation of the activity of pRB kinases during 
senescence.The p16INK4a, an inhibitor of CDK4 and CDK6 activ­
ity, is upregulated during senescence in human fibroblasts 
(Alcorta et al., 1996; Stein et al., 1999) and M0 senescence in 
human mammary epithelial cells (Wong et al., 1999).Thus, high 
p16 very likely accounts for the hypophosphorylation of pRB in 
senescent cells. Consistent with this hypothesis, p16INK4a and its 
upstream regulators such as Bmi-1, CBX7, ID1, and Ets-1 regu­
late senescence (Jacobs et al., 1999; Ohtani et al., 2001; 
Itahana et al., 2003; Gil et al., 2004) in a pRB-dependent man­
ner (Figure 2). 
Our recent data suggested that p16 upregulation during 
senescence is not nearly as universal as previously thought 
(Itahana et al., 2003). In certain fibroblast strains such as the 
commonly used WI-38 strain, p16 is clearly upregulated, while 
in other strains such as BJ fibroblasts, it is only minimally 
expressed under normal culture conditions (Itahana et al., 
2003). The fibroblasts that contain high or low p16 differ in their 
propensity to reverse senescence by the inactivation of p53 
pathway (Beausejour et al., 2003). Senescent WI-38 fibroblasts, 
which contain high p16, are essentially resistant to inactivation 
of p53 pathway, and cannot be induced to reenter cell cycle by 
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inactivation of p53. In other fibroblasts, which contain unde­
tectable p16, senescence can by reversed by p53 inactivation 
(Beausejour et al., 2003). Fibroblast strains that accumulate 
p16 differentially during senescence also differ in the presence 
or absence of senescence-associated heterochromatic foci 
(SAHF) (Narita et al., 2003). SAHF are heterochromatic DNA 
regions, where pRB was found to be colocalized (Narita et al., 
2003). SAHF are present only in human fibroblasts that contain 
high p16 during senescence, suggesting that p16 plays a role in 
generating SAHF. Interestingly, senescence in SAHF-containing 
fibroblasts is irreversible (Beausejour et al., 2003). Thus, SAHF 
possibly contribute to the stable repression of proliferation­
associated genes mediated by E2F-pRB complexes to enforce 
the senescent phenotype. 
Recently, using a p16 knockdown strategy, it was shown 
that p16 downregulation may not be functionally equivalent to 
pRB inactivation (Wei et al., 2003), leaving the possibility that 
other CDK inhibitors might play a surrogate role in cellular 
senescence. In support of this hypothesis, overexpression of 
various CDK inhibitors is known to induce a senescent pheno­
type (McConnell et al., 1998). Since p21 induction can also lead 
to the inhibition of pRB phosphorylation by inhibiting 
CDK2/Cyclin E activity (Figure 2), p16 and p21 are likely to 
cooperate to keep pRB in a hypophosphorylated form during 
senescence. Alternatively, it is possible that p21 initially and 
temporarily keeps pRB in its inhibitory form, while p16 ensures 
permanent hypophosphorylation of pRB, which practically 
makes senescence irreversible (Beausejour et al., 2003). 
Oncogenic and mitogenic signals induce senescence: A 
failsafe mechanism 
As senescence is regulated by various tumor suppressors, it 
could function as a natural barrier to tumorigenesis. This 
hypothesis could be directly tested by subjecting a normal cell 
to potential oncogenic or mitogenic stimuli. Indeed, activated H-
RAS (V12) was found to induce premature senescence in pri­
mary rodent and human cells (Serrano et al., 1997). Depending 
on the cellular context, induction of senescence by oncogenic 
signals such as activated H-RAS depends on either or both p53 
and p16INK4a tumor suppressor proteins (Palmero et al., 1998; 
Lin and Lowe, 2001). 
Since RAS signaling involves the RAF-MEK-ERK pathway, 
it is conceivable that other components of this pathway can also 
induce premature senescence. Indeed, oncogenic RAF and 
constitutive expression of mitogen-activated protein (MAP) 
kinase mimic RAS-induced premature senescence in IMR90 
fibroblasts (Zhu et al., 1998; Lin et al., 1998). Furthermore, dur­
ing oncogenic RAS-induced premature senescence, the RAF-
MEK-ERK pathway activates p38 MAPK, and inhibition of p38 
activity results in a failure to induce premature senescence by 
activated RAS (Wang et al., 2002). Constitutively active MKK3 
and MKK6, which activate p38 MAPK by phosphorylation, can 
also induce premature senescence by upregulating p53 and 
p16INK4a in human fibroblasts (Wang et al., 2002). 
Apart from p53, PML, ARF, and p16INK4a, other proteins are 
also likely to mediate the H-RAS response. For example, 
recently, a genetic suppressor element (GSE) screen identi­
fied Seladin-1 as a target gene that is involved in H-RAS­
induced premature senescence (Wu et al., 2004). 
Interestingly, Seladin-1 encodes an oxidoreductase enzyme 
involved in cholesterol metabolism (Wu et al., 2004). Further 
studies on Seladin-1 demonstrated that it is an effector of 
RAS-induced reactive oxygen species (ROS) signaling (Wu et 
al., 2004). 
A careful analysis of oncogenic, mitogenic, and other hyper­
proliferative signals is likely to reveal more cases of premature 
senescence induction by such signals in primary cells, which in 
all likelihood represents a failsafe mechanism. For example, 
similar to activated H-RAS expression, E2F1 overexpression, a 
potent mitogenic signal, leads to premature senescence in nor­
mal human fibroblasts (Dimri et al., 2000). Premature senes­
cence induction by E2F1 depends on the p53 status of the cells 
and is mediated by transcriptional induction of p14ARF by E2F1 
(Dimri et al., 2000). Constitutive overexpression of E2F3 also 
results in induction of senescence in a transgenic mouse model 
and cultured MEFs (Denchi et al., 2005). In this study, it was 
found that a sustained E2F activity, which provides a hyperpro­
liferative signal, induced senescence-like features in mouse 
pituitary gland (Denchi et al., 2005). This report is significant 
because it indicates that senescence induction by hyperprolifer­
ative signals is not merely an in vitro phenomenon. 
Recently, it was shown that the overexpression of onco­
genic ERBB2 also upregulates p21 and induces premature 
senescence in MCF-7 cells (Trost et al., 2005). The induction of 
ERBB2 in this setting causes p53-independent p21 upregula­
tion and premature senescence, which can be reversed by the 
inhibition of p38 MAPK or functional inactivation of p21 by anti­
sense oligonucleotides (Trost et al., 2005). 
Beyond senescence:The road to the cancer highway 
Primary cells induce senescence in response to potential onco­
genic signals. What happens when the induction of senescence 
fails to occur due to malfunction of tumor suppressors? Cancer 
is a multistep process; hence, abrogation of senescence alone 
does not lead to tumor formation. Nevertheless, the road starts 
from here. Recent elegant studies from the laboratories of 
Weinberg and Hahn clearly demonstrate that the first step in 
creating an in vitro model of human cancer involves the abroga­
tion of cellular senescence (Hahn et al., 1999; reviewed in 
Boehm and Hahn, 2005). These studies show that a combina­
tion of SV40 large T, small t, hTERT, and H-RAS is able to trans­
form a variety of normal human cell types such as fibroblasts, 
embryonic kidney cells, mammary epithelial cells, ovarian 
epithelial cells, and endothelial cells (Boehm and Hahn, 2005). 
Abrogation of senescence can be achieved by SV40 large 
T, a combination of HPV oncoproteins E6 and E7, E1A and 
MDM2 coexpression, or the use of short inhibitory (sh) RNA 
against pRB and p53 ((Hahn et al., 1999; Seger et al., 2002; 
Voorhoeve and Agami, 2003; Boehm and Hahn, 2005). Since 
the INK4a/ARF locus is an upstream regulator of both pRB and 
p53 (reviewed in Lowe and Sherr, 2003; Sharpless, 2005), vari­
ous mutations in this locus presumably can also substitute 
SV40 large T function in transformation assays, albeit at a lower 
efficiency depending on the nature of the mutation. For exam­
ple, a combination of hTERT and H-RAS or c-MYC is sufficient 
to transform Leiden HDFs (human diploid fibroblasts), which 
bear an INK4a/ARF mutation resulting in p16INK4a deficiency 
(Drayton et al., 2003). Similarly, a combined knockdown of 
p16INK4a and p53 by the RNAi approach, together with SV40 
small t, hTERT, and H-RAS, causes transformation of normal 
human fibroblasts (Voorhoeve and Agami, 2003). 
Compared to human cells, murine cells are clearly less rigid 
in terms of requirements for different genetic mutations for 
transformation (reviewed in Rangarajan and Weinberg, 2003). 
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Nevertheless, bypass of senescence is also essential for 
murine cell transformation. Established immortal MEF cell lines 
have often lost p53 or p19ARF. MEFs deficient in p19ARF are high­
ly susceptible to oncogenic transformation and resistant to H-
RAS-induced senescence (Sharpless et al., 2004). The H-RAS 
induced senescence can also be abrogated by other potential 
oncogenes, such as hDRIL and BCL6 (Peeper et al., 2002; 
Shvarts et al., 2002), which indirectly affects pRB and p53 path­
ways of senescence. For example, BCL6 overrides p53 pathway 
by inducing cyclin D1 expression (Shvarts et al., 2002), while 
hDRIL targets pRB pathway by binding to E2F1 (Peeper et al., 
2002). These potential oncogenes strongly cooperate with H-
RAS to transform mouse and human cells. Similarly, downregu­
lation of Seladin-1 expression by sh RNA, together with hTERT 
and H-RAS, not only overcomes RAS-induced senescence, but 
also transforms human fibroblasts (Wu et al., 2004). Deficiency 
of transcription factor DMP-1, which works upstream of ARF, 
also promotes H-RAS-induced transformation in MEFs (Inoue 
et al., 2000; Sreeramaneni et al., 2005). Thus, malfunction of 
senescence and tumor suppressor pathways facilitate transfor­
mation by oncogenes in human and mouse cells. 
Senescence in cancer treatment: Putting a roadblock in 
the cancer highway 
So far, most studies have suggested that the failure of senes­
cence-induction pathways in conjunction with activated onco­
genes possibly leads to tumor formation in vivo. However, an 
important question is, can senescence still be induced in 
tumors to stop further growth? Indeed, several recent studies 
have shown that chemotherapeutic drugs and radiation can 
induce senescence in tumor cells (reviewed in Roninson, 2003). 
Quite often, tumors develop resistance to chemotherapeutic 
drug-induced apoptosis. Senescence induction in such cases 
could serve as a backup plan to inhibit the growth of tumor cells. 
Indeed, recently, it was reported that a combined treatment of 
cells with pan caspase inhibitor (Q-VD-OPH) and doxorubicin 
greatly accelerates senescence and leads to the reversal of 
drug resistance in several tumor cell lines (Zheng et al., 2004). 
The induction of senescence in cultured tumor cells by 
DNA-damaging agents is encouraging, but the most important 
question is, does senescence response to chemotherapeutic 
drugs occur in vivo, and if so, does the therapy-induced senes­
cence contribute sufficiently to the therapeutic efficiency? 
Recent studies provide compelling evidence that cellular senes­
cence can indeed be induced in vivo by chemotherapeutic 
drugs. In the first study, te Poele et al. stained newly sectioned 
archival breast tumors from patients who had undergone a 
chemotherapy regimen for the SA-β-gal marker and p53 and 
p16INK4a proteins (te Poele et al., 2002). While normal tissues 
adjacent to the tumors were devoid of SA-β-gal, importantly, 15 
out of 36 (41%) tumors stained positive for SA-β-gal marker (te 
Poele et al., 2002). Authors also showed that the tumor sections 
from the patients that did not receive chemotherapy stained 
positively for SA-β-gal only in 10% of the cases, and this stain­
ing was in few isolated cells compared to many intense patches 
of staining present in treated tumor sections. Furthermore, 
intense SA-β-gal staining was correlated with high p16INK4a, a 
protein known to be upregulated during senescence. Although 
authors did not attempt to correlate SA-β-gal staining to sur­
vival, it was speculated that senescence induction by 
chemotherapy results in a stable disease rather than the regres­
sion of tumor, a situation often noticed during treatment by cyto­
toxic drugs in patients (te Poele et al., 2002). The induction of 
accelerated or premature senescence during chemotherapy 
treatment of human lung cancer in vivo was also recently 
demonstrated (Roberson et al., 2005). Although the sample 
size in this study was very small, it was found that two of the 
three patients treated with carboplatin and taxol intensely 
expressed SA-β-gal, while another three samples from untreat­
ed patients showed no significant SA-β-gal staining (Roberson 
et al., 2005). 
A study by Schmitt et al. also provides a clear evidence for 
the role of senescence in cancer chemotherapy in a transgenic 
mouse model (Schmitt et al., 2002). The authors showed that 
CTX (cyclophosphamide), a chemotherapy drug, is able to 
engage a senescence program when apoptosis is inhibited by 
Bcl2 overexpression during Eµ-Myc-induced lymphoma in wild­
type p53-containing transgenic mice. As a result, Bcl2 and wild­
type p53-expressing lymphoma did not progress, and the mice 
had a better prognosis after CTX treatment (Schmitt et al., 
2002). Induction of the senescence-like phenotype was also 
observed in rat mammary tumors undergoing treatment with 
chemopreventive agents (Christov et al., 2003). Thus, 
chemotherapeutic drugs can induce a senescence-like stage in 
vivo and in vitro by upregulating p53 and/or p16INK4a. 
More than 90% of tumors contain readily detectable telo­
merase activity (Kim et al., 1994). Telomerase, and various 
telomerase-regulatory and telomere binding proteins, are 
thought to regulate telomere length in a cell (Smogorzewska 
and de Lange, 2004). In principle, telomerase and telomerase­
regulatory proteins can be targeted to cause telomere dysfunc­
tion and induce apoptosis or senescence in precancerous and 
tumor cells (Shay and Wright, 2002). Indeed, several telomer­
ase inhibitors are known to induce senescence or apoptosis in 
tumor cells (Damm et al., 2001, Seimiya et al., 2002, Riou et 
al., 2002, Kim et al., 2003; Preto et al., 2004). Recently, inhibi­
tion of tankyrase 1, which poly (ADP-ribosyl)ates TRF1, was 
shown to cooperate with a telomerase inhibitor MST-312 to 
cause telomere shortening and rapid cell death (Seimiya et al., 
2005). Combined treatment of cells with telomerase inhibitors 
and other regulators of telomerase may be helpful when 
tumors develop resistance to telomerase inhibitors alone 
(Seimiya et al., 2005). 
Senescence may promote tumorigenesis: An unwanted 
side effect 
An interesting question is what could be the side effect of the 
induction of senescence by chemotherapeutic drugs, and what 
could compromise the efficacy of treatment by these drugs? It 
has been proposed that senescence in some settings may actu­
ally promote tumor progression; possibly by secreting certain 
matrix metalloproteases, growth factors, and cytokines (Krtolica 
et al., 2001; reviewed in Campisi, 2005). In particular, senescent 
fibroblasts were shown to facilitate tumorigenesis by immortal 
premalignant epithelial cells (Krtolica et al., 2001). 
It is important to note that in a therapeutic setting, both nor­
mal host and tumors cells are being treated with senescence­
inducing agents. Although induction of senescence in the tumor 
cell itself is unlikely to promote any more tumorigenicity, its 
induction in normal cells by chemotherapeutic drugs may facili­
tate tumorigenesis by cells that are not yet fully tumorigenic. 
Based on a recent study by te Poele et al., normal cells adjacent 
to tumors appear to be less receptive to senescence induction 
by chemotherapeutic drugs (te Poele et al., 2002). Clearly, more 
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studies are needed to address this question of facilitation of 
tumorigenesis by senescent cells during chemotherapy of 
tumors in patients. 
Concluding remarks 
In this review, I have highlighted the role of senescence in can­
cer. Senescence is not only a normal physiological response to 
accrued cell divisions in culture, but is also very likely a 
response to potential oncogenic events that a cell might 
encounter. Thus, a senescence response is elicited by DNA 
damage and oncogenic and mitogenic signals. In this scenario, 
senescence acts as a failsafe mechanism. Mutations in p53 
and/or pRB are a common occurrence in various cancers. 
INK4a/ARF locus, which is an upstream regulator of p53 and 
pRB, is also a target of many somatic and genetic mutations. 
These mutations often cause a bypass of cellular senescence 
and cooperate with other oncogenes in transformation assays, 
thus attesting to the importance of senescence in cancer. The 
take-home message is that a tumor will not come into exis­
tence unless it has bypassed senescence. The fascinating part 
here is that despite the fact that tumors have bypassed the 
common pathway(s) of senescence, they retain the ability to 
undergo senescence in response to treatment with a variety of 
therapeutic agents. 
Several in vitro studies suggest that chemotherapeutic 
drugs can induce a senescence-like phenotype. A limited num­
ber of in vivo studies in the human and mouse models provide 
proof of principle for the concept of induction of accelerated 
senescence by chemotherapeutic drugs. Clearly, more studies 
are needed to substantiate these findings, particularly in human 
cancers. Further caution is also warranted, because senes­
cence induction in normal cells can facilitate tumor progression 
under certain circumstances. Thus, a critical degree of senes­
cence may be the prerequisite for successful treatment using 
chemotherapeutic drugs. Although it is still unclear how much 
therapy-induced senescence can contribute to the therapeutic 
efficiency, it is likely to result in a stable disease rather than the 
regression of tumors. Apart from chemotherapeutic drugs, 
senescence induction can also be achieved by small molecules 
that directly target senescence-regulatory genes and under- or 
overexpression of various genes involved in senescence. In 
summary, senescence has a lot to do with cancer development, 
and a better understanding of the senescence induction path­
ways will greatly contribute to the development of effective can­
cer treatment strategies. 
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